TcTASV-C蛋白联合U-Omp19佐剂可诱导抗致死性克氏锥虫攻击的保护性免疫
本研究评估了克氏锥虫毒力因子TcTASV-C蛋白作为预防性疫苗抗原的性能,并测试了氢氧化铝、皂苷和U-Omp19等佐剂的组合。在小鼠模型中,TcTASV-C联合U-Omp19免疫后,小鼠在致死性克氏锥虫株攻击下表现出最低的寄生虫血症和40%的生存率提升,而其他免疫组死亡率达100%。该方案诱导了IFN-γ和IL-17细胞反应及裂解性抗体。
要点
- TcTASV-C联合U-Omp19为最佳预防性疫苗方案
- 该方案使小鼠在致死性攻击下生存率提高40%
- 保护机制与IFN-γ、IL-17及裂解性抗体相关
核心结论
- TcTASV-C蛋白与U-Omp19佐剂联合免疫可诱导保护性免疫,提高小鼠在致死性克氏锥虫攻击下的生存率。
研究设计与样本
- 小鼠模型,比较TcTASV-C与氢氧化铝、皂苷和/或U-Omp19不同组合的免疫方案。
主要发现
- TcTASV-C联合U-Omp19免疫组小鼠寄生虫血症最低,攻击后生存率提高40%,而其他免疫组死亡率100%。
- 该免疫方案诱导了产生IFN-γ和IL-17的细胞反应以及裂解性抗体。
关键数值与推荐
- 生存率提高40%(TcTASV-C+U-Omp19组 vs 其他免疫组100%死亡率)。
临床怎么用
- 提示TcTASV-C与U-Omp19组合可作为恰加斯病疫苗的候选方案,需进一步临床前评估。
局限性
- 研究仅在小鼠中进行,尚未在人体验证;需进一步评估安全性和免疫原性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The development of a Chagaś disease vaccine has yet the need for the identification of novel combinations of antigens and adjuvants. Here, the performance of TcTASV-C proteins that are virulence factors of trypomastigotes and belong to a novel surface protein family specific for T. cruzi, have been evaluated as antigens for a prophylactic vaccine. Several immunization schemes in which TcTASV-C was combined with aluminum hydroxide, saponin and/or U-Omp19 were assayed. Aluminum hydroxide and saponin were assayed together to trigger different pathways of the immune response simultaneously. U-Omp19 is a promising novel adjuvant able to promote a Th1 immune response with IFNg production, thus an interesting molecule to be tested as adjuvant for the control of T. cruzi infection. Therefore, U-Omp19 was added to the aluminum hydroxide-saponin formulation as well as assayed individually with TcTASV-C. The immunization with TcTASV-C and U-Omp19 had the best performance as a prophylactic vaccine. Mice presented the lowest parasitemias and improved survival by 40% after being challenged with a highly virulent T. cruzi strain, which promoted 100% mortality in all other immunized groups. Immunization with TcTASV-C and U-Omp19 triggered cellular responses with IFN-γ and IL-17 production and with lytic antibodies that could explain the protection achieved by this vaccination scheme. To our knowledge, this is the first time that U-Omp19 is tested with a defined T. cruzi antigen in a vaccine formulation.
引用
- Caeiro LD, Masip YE, Rizzi M, et al. The Trypanosoma cruzi TcTASV-C protein subfamily administrated with U-Omp19 promotes a protective response against a lethal challenge in mice. Vaccine. 2020. PMID: 33071003. doi:10.1016/j.vaccine.2020.10.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。